Neuroendocrine tumor (NET) occurring in association with other endocrine syndromes forms a distinct entity. The aim was to assess the therapy response profile of the routine peptide receptor radionuclide therapy (PRRT) in this relatively uncommon but clinically challenging subgroup of patients. A retrospective analysis was undertaken from the case records from those who were treated with 177Lu-...

BACKGROUND In order to obtain a reliable 177Lu-DOTATATE therapy dosimetry, it is crucial to acquire accurate and precise activity measurements with the radionuclide calibrator, the SPECT/CT camera, and the NaI(Tl) well counter. The aim of this study was to determine, in a clinical context, the accuracy and the precision of their activity quantification over a range of activities and time. Ninet...

Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment patients with neuroendocrine tumours for over two decades. It not until recently, however, it achieved regulatory approval. The currently approved regimen one-size-fits-all scheme, i.e. all receive fixed activity radiopharmaceutical (177Lu-DOTATATE) and number cycles. Several research g...

PurposePatient-specific dosimetry in MRT relies on quantitative imaging, pharmacokinetic assessment and absorbed dose calculation. The DosiTest project was initiated to evaluate the uncertainties associated with each step of clinical workflow through a virtual multicentric trial. This work presents generation simulated SPECT datasets based GATE Monte Carlo modelling its corresponding experiment...